Supplier of key reagents for drug development.

+86-15801534258
info@nebulabio.cn
NebuTools™ Polyethylenimine, Linear, MW40000 (Transfection Reagents)

Product Description:

NebuTools™ Polyethylenimine, Linear, MW 40000 (Transfection Reagents) is a transfection reagent designed for molecular biology and cell biology experiments, primarily used to efficiently introduce exogenous DNA, RNA, or other nucleic acid molecules into eukaryotic cells. This linear Polyethylenimine (PEI), with a molecular weight (MW) of 40,000, CAS: 49553-93-7, serves as a transfection reagent for delivering nucleic acids such as plasmid DNA, siRNA, and mRNA into cells. It is characterized by high efficiency, low toxicity, and suitability for a wide variety of cell types. The working principle is that PEI is a cationic polymer with numerous amino groups along its molecular chain, enabling it to bind electrostatically with negatively charged nucleic acid molecules (such as DNA or RNA) to form stable complexes. These complexes enter cells via endocytosis and subsequently release the nucleic acids from endosomes, allowing them to be expressed or function within the cell.


Product Attributes:

CAS: 49553-93-7

Molecular Formula: (CH₂CH₂NH)ₙ

Molecular Weight: 40000

Aliases: PEI40000; Polyethylenimine Hydrochloride, 40000; Polyethylenimine Linear 40000


Key Advantages:

(1) High Transfection Efficiency:** Suitable for various hard-to-transfect cell lines, such as primary cells, suspension cells, and stem cells.

(2) Low Cytotoxicity:** Compared to other transfection reagents (e.g., liposomes), PEI exhibits lower cytotoxicity.

(3)Cost-Effective:** Low cost, suitable for large-scale experiments.

(4) Stability:** The formed nucleic acid-PEI complexes have high stability, suitable for long-term experiments.


Applications:

(1) Gene Expression Studies: Transfecting plasmid DNA into cells to study gene function.

(2) RNA Interference: Delivering siRNA or shRNA for gene silencing experiments.

(3) Protein Production: Expressing recombinant proteins in mammalian cells.

(4) Gene Editing: Delivering CRISPR-Cas9 components for gene editing experiments.

(5) Vaccine Development: Delivering mRNA for vaccine research and development.


Release time:2026-03-12